LOW-DOSE WEEKLY CIDOFOVIR AS AN EFFECTIVE PROPHYLACTIC ALTERNATIVE TO LETERMOVIR FOR PRE-ENGRAFTMENT CMV IN ALLOGENEIC HSCT (EBMT 2026) - Mar 14, 2026 - Abstract #B066; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "In a direct efficacy comparison, low-dose weekly cidofovir demonstrates breakthrough rates and a safety profile akin to letermovir for pre-engraftment CMV prophylaxis. For geographical regions where letermovir is unavailable or cost-prohibitive, this protocol provides a highly effective, practical, and cost-conscious prophylactic alternative, potentially mitigating early CMV-related graft compromise without the myelosuppressive risks of ganciclovir. It warrants consideration as a strategic option in global transplant practice."
Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease
|
|
Santanu Sen1; Nirali Sanghvi1; Manam Mehra1; Juhi Mehrotra2; Shyla Sen3
|